Search Results - tils

3 Results

Sort By:

Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy

Abstract: Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual's adaptive immune system to fight against cancer, with fewer side-effects...

Published: 4/8/2024 | Inventor(s): Warren Leonard, Dalton Hermans, Luca Gattinoni, Leonard Neckers

Keywords(s): act, Adoptive T Cell Therapy, CAR T Cells, CD8+ T Cells, Gattinoni, Interleukin-21, Lactate Dehydrogenase Inhibitor, LDH, Neckers, Preconditioning, TCR-engineered T Cells, TILS

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients

Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells (neoantigens). Neoantigen specific TIL administration in patients has resulted in long-term regression of certain metastatic cancers. However, current procedures for TIL therapy are highly invasive, labor-intensive, and...

Published: 4/8/2024 | Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy

Abstract: Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial cancers, most patients do not respond to treatment. Although the mechanisms underlying this variable response to therapy are not fully elucidated, the phenotype of...

Published: 4/8/2024 | Inventor(s): Steven Rosenberg, Gregoire Altan-Bonnet, Sri Krishna, Paul Robbins, Frank Lowery

Keywords(s): act, Adoptive T Cell Therapy, Cancer Immunotherapies, CAR, CD-39 Receptor, CD3-Receptor, CD-69 Receptor, chimeric antigen receptor, Lowery, Rosenberg, T Cell Receptor, TCR, TILS, Tumor-Infiltrating T-Lymphocytes

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics